Comparison of Strategies to Study Pediatric Pulmonary Vascular Disease Outcomes Using Bioinformatics (U01)
The summary for the Comparison of Strategies to Study Pediatric Pulmonary Vascular Disease Outcomes Using Bioinformatics (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Comparison of Strategies to Study Pediatric Pulmonary Vascular Disease Outcomes Using Bioinformatics (U01): Under this Funding Opportunity Announcement (FOA), the National Heart, Lung, and Blood Institute (NHLBI) invites applications to support a comparison of the ability of two data sources, electronic health records and traditional prospective patient-based clinical and research data, to answer research questions regarding the natural history, longitudinal outcomes, and phenotypes of therapeutic response for pediatric pulmonary vascular disease (PVD).There will be one award for a Bioinformatics Clinical Coordinating Center (BCCC).Because PVD in children is rare and heterogeneous, the applicant will develop, implement, and evaluate the strengths and limitations of two data collection approaches to answer research questions regarding the natural history, longitudinal outcomes, and phenotypes of therapeutic response.The prospective data collection strategies proposed should include utilizing: 1) electronic health records (EHR) and 2) traditional prospective patient-based clinical and research data.Applicants should propose: 1) methods, plans, and expertise required to develop the two data sources; 2) at least three research pediatric PVD questions that the data collection strategies can address; and 3) a method to compare the usefulness of the two data sources to answer the research questions. This work will elucidate the value of EHR in answering real-world clinical management questions with the ultimate goal of improving health outcomes for children treated for PVD, and optimizing clinical trial design.The work will require multidisciplinary and multi-institutional team coordination that includes expertise in bioinformatics and computational science and clinical knowledge and access to pediatric patients with PVD.
|Federal Grant Title:||Comparison of Strategies to Study Pediatric Pulmonary Vascular Disease Outcomes Using Bioinformatics (U01)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-HL-14-005|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Lung Diseases Research|
|Current Application Deadline:||Feb 21, 2013|
|Original Application Deadline:||Feb 21, 2013|
|Posted Date:||Jun 01, 2012|
|Creation Date:||Jun 01, 2012|
|Archive Date:||Mar 24, 2013|
|Total Program Funding:||$1,800,000|
|Maximum Federal Grant Award:||$1,800,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)
- • Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (...
- • Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial...
- • Management of Asthma in Primary Care - Bioinformatics Center (U24 - Clinical Trial Require...
- • Management of Asthma in Primary Care - Clinical Center (UG3/UH3 - Clinical Trial Required)
- • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models
- • Lung Response to Inhaled Highly Toxic Chemicals
- • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...